logo
Former FDA chief: Ultraprocessed foods are ‘addictive' like drugs

Former FDA chief: Ultraprocessed foods are ‘addictive' like drugs

Yahoo9 hours ago
(NewsNation) — Ultraprocessed foods engineered with fat, sugar and salt are 'addictive' and driving America's obesity crisis, according to a former Food and Drug Administration commissioner who argues the problem goes far beyond individual willpower.
Dr. David Kessler, who led the FDA and later ran Operation Warp Speed, said obesity rates have jumped from 13% in the 1960s to 42% today because of what he calls 'ultraformulated foods' that trigger dopamine responses similar to addictive drugs.
'We took fat, sugar and salt, put it on every corner, made it available 24/7, made it socially acceptable to eat any time,' Kessler said Thursday on NewsNation's 'Elizabeth Vargas Reports.' 'We're living in a food carnival. What did we expect to happen?'
Air pollution, herbal remedies tied to lung cancer risk: Study
Four out of 10 American adults are classified as obese, with up to a quarter of them morbidly obese. Kessler, author of the new book 'Diet, Drugs and Dopamine,' said the real health threat comes from toxic abdominal fat that infiltrates the liver, pancreas and heart.
Around 25% of American men will develop heart failure in their lifetime, 33% will develop diabetes, and 25% will have a stroke, according to Kessler.
Unlike traditional processed foods that contain preservatives or stabilizers, ultraformulated foods combine fat, sugar and salt in ways that affect the brain's reward systems, Kessler explained.
Food companies design products to hit what they call the 'bliss point' that triggers these reward circuits.
Fact check: Are there 1.4M illegal immigrants on Medicaid?
'It's not like amphetamine or cocaine, but I certainly use food,' said Kessler, who gained 40 pounds after running Operation Warp Speed. 'It's not about willpower. It's about biology.'
The former FDA chief said Americans need to change how they view these foods, comparing the effort to the successful campaign against tobacco that transformed cigarettes from glamorous to deadly in public perception.
Kessler also weighed in on GLP-1 drugs like Ozempic, which federal researchers are now studying for use to treat alcohol addiction in patients not overweight.
These medications work by slowing food through the stomach to the point of nausea, counterbalancing reward circuits, though Kessler said more research is needed.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas
Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas

Yahoo

time39 minutes ago

  • Yahoo

Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas

Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX) announced its plan to integrate its iLet Bionic Pancreas automated insulin delivery/AID system with Abbott's future dual glucose-ketone sensor in the US. The collaboration aims to enhance real-time decision-making support for individuals with diabetes. The iLet Bionic Pancreas received FDA clearance in May 2023 and is distinguished as the first and only AID system that autonomously makes 100% of insulin dosing decisions. This eliminates the need for carb counting or manual insulin correction calculations for users, though they still need to be 'carb aware.' The system currently supports Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and the new agreement deepens the ongoing partnership between Beta Bionics and Abbott. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The new dual sensor is currently under development and is built on the same form factor as Abbott's FreeStyle Libre 3 Plus and will continuously monitor both glucose and ketone levels. Ketone monitoring is a crucial advancement as it can help detect early signs of diabetic ketoacidosis, which is a serious complication of diabetes. Abbott's dual glucose-ketone sensor has received FDA breakthrough device designation. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products. Beta Bionics Inc. (NASDAQ:BBNX) is a commercial-stage medical device company. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies
BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

Yahoo

time2 hours ago

  • Yahoo

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best new stocks to buy now. On June 18, BrightSpring Health Services announced that its specialty pharmacy, called Onco360, has been chosen as the national pharmacy partner for several newly approved therapies. These innovative treatments target advanced cancers and rare genetic disorders. BrightSpring delivers care and clinical solutions to 400,000+ customers, clients, and patients daily across all 50 states. Onco360 will provide access, education, data, and expert support for patients suffering from advanced ovarian and lung cancers, as well as neurofibromatosis type 1. A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room. Onco360 has been selected as a pharmacy partner for the following specific medication therapies: GOMEKLI, which is approved for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas/PN not suitable for complete resection; AVMAPKI FAKZYNJA CO-PACK, which is approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer/LGSOC who have received prior systemic therapy; and IBTROZI, which is approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that operates through 2 segments: Pharmacy Solutions and Provider Services. Onco360 is a national, independent Oncology Pharmacy and clinical support services company. While we acknowledge the potential of BTSG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments
Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments

Yahoo

time2 hours ago

  • Yahoo

Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments

Waystar Holding Corp. (NASDAQ:WAY) is one of the best new stocks to buy now. On June 23, Waystar announced the findings of a commissioned study conducted by Forrester Consulting. The study is titled 'AI in Healthcare Payments Software: A Strategic Imperative,' and revealed that AI is becoming increasingly critical in revenue cycle management/RCM due to its proven impact and measurable ROI. The research shows acceleration in AI adoption within healthcare. 82% of healthcare leaders now consider AI an integral part of their RCM operations, with 70% identifying it as a top organizational priority. The study also found that AI is delivering improvements in key revenue cycle metrics, such as a 13% to 37% improvement in high-impact areas such as claim accuracy, denial prevention, workforce efficiency, and payment speed. A medical professional with a patient explaining the effects of neurostimulation treatments. Trust in AI is growing, with 60% of decision-makers reporting increased confidence since implementing AI. ~ 70% of healthcare leaders view AI as a high or critical organizational priority, and 60% plan to increase their AI investment. The study is based on responses from 300+ healthcare leaders and highlights a preference for existing RCM software partners when it comes to AI capabilities. Waystar serves ~30,000 clients and represents over 1 million distinct providers, including 16 of the top 20 institutions on the US News Best Hospitals list. Waystar Holding Corp. (NASDAQ:WAY) develops a cloud-based software solution for healthcare payments. While we acknowledge the potential of WAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store